Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 300255.SZ

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Price to Book Ratio (P/B) on January 14, 2025: 9.39

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Price to Book Ratio (P/B) is 9.39 on January 14, 2025, a 62.41% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd. 52-week high Price to Book Ratio (P/B) is 12.18 on October 25, 2024, which is 29.79% above the current Price to Book Ratio (P/B).
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd. 52-week low Price to Book Ratio (P/B) is 3.90 on February 05, 2024, which is -58.43% below the current Price to Book Ratio (P/B).
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 6.55.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
Shenzhen Stock Exchange: 300255.SZ

Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

CEO Ms. Hao Cai
IPO Date Aug. 19, 2011
Location China
Headquarters Zhengding County High-tech Ind Dev Zone
Employees 1,410
Sector Health Care
Industries
Pharmaceuticals Biotechnology Chemicals & Advanced Materials Petrochemicals
Description

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China. Its products include crude heparin sodium, heparin sodium raw materials, heparin sodium injections, low molecular weight heparin calcium raw materials and injections, enoxaparin sodium raw materials and injections, nadra Heparin calcium raw materials, nadroparin calcium injections, and dalteparin sodium raw materials and injections. The company was founded in 2000 and is based in Shijiazhuang, China.

StockViz Staff

January 15, 2025

Any question? Send us an email